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Abstract        199 words (max 200) 
 
Purpose of review: Knowledge on and understanding of the pathophysiology of 
inflammatory bowel disease (IBD) is growing monthly. Important insights from the 
last years are summarized in this review. 
Recent findings: Further genetic risk factors for IBD have been identified and 
confirmed. Novel studies analyzing the function of those susceptibility factors have 
improved our understanding of pathophysiological pathways. Both the innate and the 
adaptive immune system are found to be deregulated. In contrast to frequent 
notions that only 25% of genetic heritability are explained by the published findings 
this could be much higher. Epigenetic changes may contribute to heritability. 
Epigenetic modification can be triggered by environmental factors. Those 
environmental factors have been shown not only to influence immunological 
functions and the intestinal barrier. They also affect the composition of the gut 
microbiome which then interacts with the mucosal immune system. From recent data 
it is clear that the gut microbiome as well as innate defense mechanisms and barrier 
aspects bidirectional regulate each other contributing to a delicate balance that 
warrant further detailed investigations. 
Summary: New therapies will be emerging from the concept of a bidirectional 
interplay between environment and microbiome on one hand and defence 
mechanisms on the other.   
 
 3 
Introduction 
Gastroenterologists and researchers working in the field of IBD are in both a lucky as 
well as a difficult situation. Research on IBD pathophysiology in these days is highly 
innovative, going permanently beyond old limits and borders. IBD-scientists have to 
continuously broaden their view, get familiar with new fields of research and update 
their knowledge. We are indeed lucky that IBD-research is now “cutting edge” in 
human genetics of polygenetic diseases, innate and adaptive immunology, cell 
signalling, cell biology, ecology or microbiology. This allows trans-disciplinary 
networking finally leading to most interesting research projects and stimulating new 
insights – not only for gastroenterology but for all the disciplines mentioned above. 
However, this goes hand in hand with a growing problem of keeping informations 
updated and being familiar with all relevant new developments and insights.  
Many of the new findings have changed our concepts about Crohn’s disease (CD) 
and ulcerative colitis (UC) or about the many different “Crohn’s diseases” as some 
colleagues suggest. The innate immune system, early responses to bacterial products 
and the modulation of T-cell responses are important aspects that will be discussed 
in this review. Due to the multitude of directions IBD-research is presently taking 
such an overview indeed can only reflect the opinion of the authors as indicated by 
the journal’s name “Current Opinion”.  
 
New insights into heritability of IBD 
 
The important contributions by consortia investigating genetic IBD risk factors have 
confirmed that IBD are complex diseases that develop in genetically susceptible 
individuals carrying one or more genetic risk factors triggered by the influence of 
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environmental factors. As many of the identified risk gene products are involved in 
the recognition and processing of microbial antigens at the mucosal surface an 
abnormal processing of such microbial derived molecules by compounds of the 
innate immune system is generally assumed to play a key role in initiating 
inflammation, followed by an exaggerated adaptive immune response with a trend to 
chronification and relapse. Secretion of pro-inflammatory molecules and local or 
distant tissue damage are then only a consequence of the initially unbalanced 
response. 
It is well confirmed and demonstrated by population based studies and incidence 
cohorts that there is a heritability for IBD and relatives of an IBD patient have a 
higher risk of also developing IBD as compared to the general population [1]. In the 
meantime almost 100 susceptibility loci have been replicated in IBD meaning that 
they have been found in at least two independent studies [2]. In CD a large meta-
analysis of genome-wide association studies (GWAS) has identified at least 71 
replicated loci, such as NOD2, ATG16L1, IRGM, NALP3 or the IL-23R, IL-10, IL-27, 
PTPN2 or FUT2 [2]. A recent meta-analysis in UC on six ulcerative colitis GWAS 
datasets identified 47 loci in total (29 additional risk loci to the 18 already described) 
including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and 
LSP1 [3]. Out of the 99 confirmed IBD risk loci 28 (28/71, 39% of CD loci) are 
shared between CD and UC such as members of the interleukin-23 pathway or 
transcription factors such as NK2 transcription factor related, SMAD3, STAT3, ZMIZ1, 
and c-REL [4].  This indicates that a set of core mechanisms is relevant for the 
pathogenesis of CD and UC [5]. Bacterial recognition, autophagy, endoplasmic 
reticulum stress, epithelial barrier function, T cell differentiation and function, 
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oxidative stress, and mucosal immune defenses are obviously relevant in both 
diseases [6].  
However, it is puzzling that certain loci play only a role in specific ethnicities and are 
completely absent in others. E.g. the most well know and first discovered 
susceptibility locus NOD2 does not seem to play a role in the Asian population [7]. 
Most puzzling, however, is the fact that all genetic susceptibility loci discovered so far 
were regarded to only explain 20% - 25% of the heritability found in the above 
mentioned population based studies. This is not only true for IBD but for many 
polygenetic diseases and has been called the “the mystery of missing heritability of 
common traits” [8]. However, the mystery may be smaller than we used to assume. 
In a recent analysis the concept of “phantom heritability” has been brought up. Zuk 
et al explain this concept for CD and point to the 71 confirmed loci identified by 
GWAS [2]. Generally it is assumed that CD arises from an additive effect of 
independently affected genes and thus the identified loci explain only around 22% of 
the estimated heritability [8]. In a so-called limiting-pathway model the “phantom 
heritability” would be 62.8%, and the so far discovered genetic risk factors would 
explain 80% of the currently missing heritability [8] indicating that in fact most real 
riske genes have been identified so far. What does the “limiting-pathway model” 
mean? It reflects the fact that genes and their products may not be independent but 
linked by “epistasis”. Epistasis means in the genetic world that effects of one gene or 
gene product are modified by one or several other genes or their products. On a 
genetic level they would be called modifier genes. In general, the impact of one 
mutation depends in a complicated way on many other genes or their products. 
Epistasis does not necessarily imply biochemical interaction between gene products 
but may also be dependent on those. In general epistasis means that different 
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genetic loci are not 'independent' but they influence each other directly or by their 
products and merge functionally into shared pathways (Figure 1). According to this 
attractive hypothesis outlined by Zuk and Landers the frequently heard statement 
about “missing heritability” indicating a huge amount of so far undiscovered variants 
and genetic modifications would be unjustified [8]. Rather, the missing heritability 
would be a mis-conclusion ignoring the important role of genetic interactions  and 
shared pathways [8]. Interactions of variant gene products may also secondary 
cause alterations on an epigenetic level.  
From the “missing heritability” theorem it frequently has been concluded that rare 
variants must be of large pathogenetic relevance. Therefore, deep sequencing 
studies and further genetic analysis were suggested. However, recent studies 
applying these new techniques could not affirm the assumption. Rivas and colleagues 
used pooled deep sequencing to study 56 genes from regions associated with CD in 
350 cases and controls. They further did a follow-up genotyping of 70 rare and low-
frequency protein-altering variants in 16,054 CD, 12,153 UC and 17,575 healthy 
controls [9]. Doing that they only found four additional independent risk factors in 
NOD2, two additional protective variants in IL23R, a highly significant association 
with a protective splice variant in CARD9 and associations with coding variants in 
IL18RAP, CUL2, C1orf106, PTPN22 and MUC19 [9]. This means that the rare variants 
reported explain 10- to 20-fold less of the heritability than the common variants at 
those 56 disease-associated loci [9]. Of note, there is no good argument why that 
should be different for other loci. 
In summary these important new insights into genetics of IBD and heritability 
indicate that in the future the explorations of gene-gene interactions, gene-pathway 
interactions and gene-environment interactions are likely to give us more insights 
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into IBD pathogenesis than finding new rare variants without further information of 
their function and pathway involvement. Therefore, the key focus of IBD research 
should be to study the biological role of the variants discovered so far [8]. 
 
IBD risk factors are not independent 
As mentioned there may be epistasis - gene-gene, gene-protein and gene-
environment interactions - that contributes to the heritability and pathogenesis of 
IBD (Figure 1). In the last years we have gained a number of insights in those 
epistasis effects.  
The NOD2 gene was the first susceptibility gene identified for CD. It still remains the 
strongest genetic determinant. NOD2 is an intracellular pathogen recognition 
receptor (PRR) binding bacterial wall muramyl-dipeptide (MDP) of the peptidoglycan 
of Gram-positive and Gram-negative bacteria. It is expressed in antigen-presenting 
cells (APCs) as well as in Paneth cells and other intestinal epithelial cells. Three 
common NOD2 disease-associated mutations and a number of rare mutations [9] 
have been identified associated with ileal CD and stricturing disease course. NOD2 is 
a “classical” example for linked pathways: In 2010 a direct interaction between Nod2 
protein and Atg16L1 was demonstrated [10] which had obvious functional 
consequences in antigen presenting cells [11] (Figure 2). CD-associated NOD2 
variants impair the MDP induced activation of the autophagy pathway [12] indicating 
the close functional connection of both variants in the pathogenesis of IBD and 
supporting the “limited pathways” concept. As a consequence of a failure to activate 
the autophagy pathway properly by Nod2 ligands in cells harboring the ATG16L1 
Thr300Ala risk variant increased production of the pro-inflammatory cytokines IL-1β 
and IL-6 has been demonstrated [13,14]. Even the development of typical circulating 
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antibodies such as anti Saccharomyces cervisiae antibodies (ASCA) may be 
influenced by these polymorphisms [15]. 
Further supporting the “limited pathways” concept are the observations that both, 
NOD2 as well as ATG16L1, can regulate the expression and secretion of IL-1β [16]. 
Activation of IL-1β as well as of IL-18 is controlled by the inflammasome complex 
[16]. The Nod-like receptor family member 3 (Nlrp3) that forms the NALP3 
inflammasome together with caspase-1 and ASC, has been shown to play a pivotal 
role for host defence against microbial pathogens [17-19] and genetic variations of 
Nlrp3 have been associated with increased susceptibility for the onset of CD [20]. 
Inflammasome activity can also be regulated by Atg16L1 and Nod2 strongly 
suggesting that the observed regulatory effects of NOD2 and ATG16L1 on IL-1β 
secretion are mediated via the inflammasome [17]  (Figure 2). These observations 
demonstrate a close functional correlation between the different CD susceptibility 
genes, NOD2, ATG16L1 and NLRP3 being involved in the immune defence against 
invading pathogens and provides a strong evidence for the relevance of the “limited 
pathways” concept. 
Satsangi and co-workers identified TLE1 to be an NOD2 interacting protein [21]. 
SNPs within TLE1 were independently associated with the susceptibility to develop 
CD, specifically with ileal disease [21]. The TLE1 risk allele appeared to be necessary 
for the development of CD in carriers of NOD2 mutations. Thus, both epistatic and 
biological interactions between TLE1 and NOD2 seem to be involved in IBD 
pathogenesis [21].  
Another important interaction discovered in the last year by IBD-researchers is the 
interplay between redox-regulation and innate immune defence which may be most 
crucial for an undisturbed barrier function at the human gut mucosa. Human β-
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defensin 1 (hBD-1) is an important anti-microbial peptide secreted by epithelial cells. 
Its function is crucially dependent on the redox state. Only after reduction of 
disulphide-bridges, hBD-1 becomes a potent antimicrobial peptide [22]. The 
modulation of the redox state of the mucosa by inflammation, by enzymatic and by 
environmental factors may profoundly influence the antibacterial activity and mucosa 
protection as well as the barrier function [22]. Importantly the redox state of the 
mucosa is not only under control of the host. The intestinal flora itself has influence 
on this parameter [23] indicating a complex network with feedback loops (Figure 2). 
Besides Atg16L1 and Nod2, other risk factors may also influence the autophagy 
pathway. Recent data indicate that a protein tyrosine phosphatase, namely PTPN2, 
regulates autophagosome formation in human intestinal cells [24,25]. A deficiency of 
PTPN2 causes impaired autophagosome formation and dysfunctional autophagy 
resulting in elevated numbers of intracellular Listeria monocytogenes and increased 
IEC apoptosis in response to tumor necrosis factor (TNF) and interferon gamma 
(IFN-γ) [24,25] (Figure 1). A novel CD-associated PTPN2 variant directly modulated 
innate immune responses to bacterial antigens such as MDP indicating a further 
crosstalk to Nod2 [24] (Figure 1). Originally, PTPN2 had been described to have a 
distinct role in T-cell development such being an important modulator of adaptive 
immunity. A recent study using T-cell specific PTPN2-deficient mice demonstrated 
that PTPN2 exerts a key role in the negative regulation of T-cell receptor dependent 
differentiation of CD8+ cells and T-cell specific deficiency of PTPN2 results in a severe 
systemic inflammation [26]. 
Taken together, these findings reveal the close functional connection of different IBD 
susceptibility genes and form another piece in the puzzle of IBD pathogenesis finally 
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clearly supporting the concept of the “limited pathways”. It can be anticipated that 
further interactions of IBD risk genes will be discovered in the near future. 
 
New immune cell populations and their role in IBD 
The above mentioned genes all have been well characterized to play a role for 
immune cell development and function either by regulating proliferation-associated 
intracellular signaling pathways, secretion of pro-inflammatory cytokines, antigen 
presentation or cellular responses to invading pathogens. Among the variety of 
immune cells, recent studies demonstrated a pivotal role for a certain subset of CD4+ 
T-cells, namely Th17 cells, as well as for innate lymphoid cells (iLC) in the 
pathogenesis of IBD. Of particular interest, differentiation of both of these cell types 
is critically dependent on the expression of RORγt transcription factor and both of 
these cell types secrete IL-17 as most prominent cytokine.  
Th17 cells are characterized by the expression of RORγt, their signature cytokine IL-
17 and the IL-23-receptor (IL-23R). Levels of RORγt as well as of IL-17 are increased 
in the intestine of IBD patients and elevated numbers of Th17 cells can be found 
[27]. Interestingly, IL-23 is required for stabilization and amplification of Th17 cells 
and variations within the IL-23R gene have been associated with onset of IBD [2]. A 
role for IL-17 and Th17 cells in the pathogenesis of chronic intestinal inflammation 
has been demonstrated by various colitis models. IL-17 knock-out protects from or at 
least ameliorates chemically-induced colitis and transfer of Th17 cells into RAG-/- 
mice induces a severe colitis in these animals [27]. The main effect of Th17 cells in 
promoting inflammation is mediated by the production of cytokines and chemokines, 
such as IL-17A, IL-17F, IL-21, IL-22 or IL-9 and by their interplay with intestinal 
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epithelial cells forcing them to release cytokines and chemokines on their own what 
finally results in the perpetuation and chronification of inflammation [27].  
In contrast to CD4+ Th17 cells, iLC are not regarded as T-cells and develop via 
distinct pathways. Whereas the development of lymph nodes of the mesenterium 
and Peyer’s patches of the intestinal mucosa is programmed during the fetal period 
in the sterile environment of the uterus isolated lymphoid follicles (ILFs) develop in 
the intestinal mucosa of the newborn child after induction by the colonizing 
microbiota. Lymphoid tissue inducer (LTi) cells express and require the nuclear 
hormone receptor RORγt for their generation [28]. Mice deficient for RORγt lacking 
those LTi cells, have no programmed lymphoid tissues, ILFs and Th17 cells. After 
epithelial damage and a subsequent barrier disruption RORγt-deficient mice develop 
severe intestinal inflammation associated with a severe weight loss [28]. This can be 
ameliorated or prevented by antibiotic treatment pointing to the important role of the 
bacterial colonization. These data point to the assumption that RORγt+ cells, 
including Th17 cells, limit DSS-induced intestinal inflammatory disease by improving 
antibacterial defence mechanisms. 
As mentioned, LTi cells belong to the newly defined family of innate lymphoid cells 
(ILC) that all express RORγt producing IL-17 and IL-22. Besides LTis, IL-22-
producing NKp46+ cells are summarized under the ILCs. LTis and mucosal NKp46+ 
cells constitutively produce most of the intestinal IL-22 and repress the symbiotic 
microbiota through epithelial expression of IL-25 [29]. This function was required 
after epithelial damage demonstrating a crucial role for RORγt+ ILCs in intestinal 
homeostasis [29]. Subsequently it may be concluded that ILCs provide immuno-
surveillance at mucosal surfaces [30]. A recent report described a selective increase 
of CD3-CD127+CD56- iLCs in inflamed intestinal tissue of CD, but not UC patients and 
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these cells feature increased expression of IL-17 A and IL-17F [31]. Further subsets 
of ILCs have been described recently: A new population present in fetal gut is 
responsive to IL-25 and IL-33 and produces large amounts of IL-13 [32]. A role of 
this ILC population in UC pathophysiology has been discussed [30]. 
 
New concepts on environmental factors 
In the first section of this review it was discussed that gene-environment interactions 
could largely contribute to the “phantom-heritability” of IBD. The notion that both 
genetic factors and environmental factors contribute to the pathophysiology of IBD is 
trivial. However, we now begin to understand that the interaction between 
environmental and genetic factors determines the pathogenesis of IBD. Obviously 
that does not only happen in an additive way (factors that come together and add to 
the pathogenesis). Those factors interact and modify each other: Environmental 
factors cause epigenetic modifications, induce metabolic pathways for which 
suddenly genetic variants become important, interact with malfunctioning pathways 
of the innate immune system or cause responses that cannot properly be resolved. 
On the other hand genetic variants change at least the micro-environment e.g. the 
composition of our gut flora, the microbiome.  
Is there any evidence for epigenetic alterations in patients with IBD? In a recent 
study Lin an coworkers found seven CpG sites that were differentially methylated in 
intestinal tissues of IBD patients [33]. This is not very conclusive so far and further 
data are desirable. 
Not only typical bacterial pathogens may be pathogenic during IBD development. 
Under certain conditions commensals can contribute to inflammation [34] as we 
knew already for the last 20 years from the studies of Duchmann and colleagues. 
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Specific gene products of specific gut bacterial strains are able to influence the 
intestinal barrier function. The metalloprotease GelE, produced by commensal strains 
of Enterococcus faecalis was shown to aggravate chronic colitis in respective mouse 
models by impairing epithelial barrier integrity [35].  
Where as the effects of the bacterial microbiome now are under detailed 
investigation knowledge on gut viruses and fungi is sparce. Viral diversity and their 
impact on the mucosal immune system are poorly understood. It is well known that 
twins and their mothers share a significantly greater degree of similarity in their 
faecal bacterial communities than do unrelated individuals [36]. In contrast, Gordon 
and coworkers demonstrated that viromes are unique to individuals regardless of 
their degree of genetic relatedness [36]. Whereas intrapersonal variation in viromes 
was minimal in the study by Reyes and colleagues over the observations time of one 
year, interpersonal variation was very high [36]. Thus the individual virome could 
contribute to the lack of concordance in more than 50% of co-twins with respect to 
the incidence of CD. It certainly has to be taken into account into further analyses of 
contributing environmental factors. A role for viruses already has been indicated by 
other studies: Viral infection dramatically augmented Nod2 signalling and increased 
the production of proinflammatory cytokines [37]. The enhanced Nod2 signaling was 
mediated by type I interferons (IFNs) indicating a role for T-cell responses [37]. The 
authors conclude that a crosstalk between type I IFNs and Nod2 signaling promotes 
bacterial recognition, but may be harmful under conditions of a viral infection [37]. 
Obviously it has to be clarified whether all intestinal viral infections have the same 
impact. An intriguing paper published in 2010 indicated that the impact of ATG16L1 
variants might be only present under concomitant infection with a norovirus [38]. 
Whether the same is true for human disease remains to be answered. Viruses may 
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alter composition of the bacterial flora and thus be an environmental trigger of 
disease outbreak.  
 
ER stress and chronic intestinal inflammmation 
Environmental factors (such as viruses) may also induce ER stress. ER stress 
activates the unfolded protein response (UPR) that has been found to play a role in 
the pathogenesis of the barrier defect contributing to CD and UC [39]. A recent study 
identified defects in the eIF2α pathway that controls protein translation and cell 
stress responses in colonic biopsy samples from patients with UC [40]. There seems 
also to be a close connection between the innate immune system and the UPR since 
activation of the XBP-1 pathway or ligation of TLR3 and TLR4 on macrophages is 
required for cell survival of ER stress in response to innate immune responses. 
Additionally, activation of XBP-1 via TLR signaling is necessary for proper cytokine 
secretion from macrophages necessary for controlling infectious situations and 
deficiency of IRE1beta, which is exclusively expressed in the intestinal epithelium 
aggravates DSS-induced colitis in the mouse model [18,39,41]. Genetic variations in 
XBP-1 and ORMDL3, two genes being essential for mediating the UPR, have been 
associated with IBD [39,42]. Mice deficient in XBP-1 revealed spontaneous small 
intestinal inflammation as well as overwhelming ER stress and hyperreactivity of the 
intestinal epithelial cells in response to cytokines and microbes [39]. Further, XBP-1 
deficiency results in dysfunction and apoptosis of Paneth cells what can also be 
observed in cells harboring the CD-associated Atg16l1 gene variant [38,39]. All in all, 
these observations fit well to the “limited-pathways concept” since dysfunction of 
genes from, at first sight, different and independent pathways, such as Nod2, 
Atg16l1 and XBP-1, converge on a functional level. In example dysfunction of each of 
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those genes results in impaired autophagy, altered or defective expression and 
secretion of cytokines and antimicrobial peptides as well as in Paneth cell 
dysfunction.   
 
Stability and instability of the gut microbiome 
As mentioned the human gut microbiome is likely to be of central importance for the 
pathogenesis of IBD. In the colon there are around 500 different species of bacteria 
mainly belonging to three phyla, Firmicutes, Bacteroides and Proteobacteria. The gut 
microbiota may be regarded as interface or mediator between the external 
environment and the immune system.  
The last year has brought new and important insights in the modifications of the 
microbiome by both the host but also by other environmental conditions. Advances in 
sequencing technologies provide new insights into the gut microbiome – insights that 
have not been possible by culture methods as a large number of intestinal bacteria 
cannot be cultured under the conditions developed. By means of the new sequencing 
methods environmental factors such as geography [43], economic living conditions, 
age, diet [44] and lifestyle have been shown to influence the composition of the 
intestinal microbiota. In fact knowledge on the composition of specific diets may 
even allow to some extend predict the composition of the gut flora [45]. It appears 
to be of high interest for the understanding of IBD pathophysiology to understand 
the interrelationship between diet and the composition of the human gut microbiome 
as new ways to manipulate the properties of the microbiota in IBD may evolve. The 
interrelationship between nutrient uptake, microbiome composition and subsequent 
modified nutrient metabolism on one hand and the immune system on the other 
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hand occurs at many levels [46]. It is a typical example for an environment-gene 
interaction as discussed above. 
The gut microbiota develops during the first days of life. Breast feeding has been 
discussed controversial regarding its impact on the development of IBD. In general it 
is assumed the breast feeding may be protective and induce an anti-inflammatory 
protective microbiota. Which factors could contribute to such a protective effect? 
Breast milk oligosaccharides are known to contribute to the development of the early 
gut microbiota by acting as decoy receptors for pathogens and as prebiotics, which 
promote the colonization of commensal bacteria [47]. Surprisingly in the dextran 
sulfate sodium (DSS) mouse colitis model adult mice that had been fostered on 
sialyl(α2,3)lactose-deficient milk were more resistant to colitis as compared with 
mice fostered on normal milk [47]. Analysis of intestinal microbiota showed different 
colonization patterns depending on the presence or absence of sialyl(α2,3)lactose in 
the milk. The presence of absence of a single oligosaccharide structure during 
fostering influences microbial composition, however, not in a way that would have 
been expected. Interestingly the presence or absence of sialyl(α2,3)lactose was 
correlated with the abundance of specific bacterial groups such as Ruminococcaceae 
which correlated with the susceptibility to DSS-induced colitis [47].  
In children with IBD the microbiome is already significantly altered: Richness and 
biodiversity of the gut microbiome were reduced in children with UC as compared 
with healthy controls and there was a further reduction of those parameters when 
steroid-non responders were compared to steroid responders [48]. Similar, the 
diversity of the oral microbiome is rescued in pediatric patients with CD [49]. 
When the microbiome of paired mucosal biopsies of adult CD patients, 6 UC patients 
and 5 healthy controls was compared by pyro sequencing a reduced microbial 
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diversity in IBD, particularly in CD, could be confirmed [50]. Firmicutes were found to 
be reduced in IBD samples in contrast to Bacteroidetes which were increased [50]. 
Similar findings were obtained when investigating micro-dissected tissue samples 
[51]. A well known commensal, Escherichia coli (E. coli) has been associated with the 
pathogenesis of IBD in adults. The population of E. coli is increased in IBD. Recent 
data suggest that this population is mostly comprised of aggregative adherent 
strains, some of which express classical virulence markers [52]. 
Interestingly genetic variants associated with CD may not only be responsible to 
variant responses or a dysfunctional microbial sensing. They seem additionally to 
have influence on the composition of the human intestinal microbiome. The NOD2 
composite genotype and the ATG16L1 genotype were found to be significantly 
associated with shifts in microbial compositions [53]. Other polymorphisms that 
influence the bacterial composition of the microbiome have been detected during the 
last year: The FUT2 (Secretor) gene encodes an α-1,2-fucosyltransferase necessary 
for the expression of ABO group antigens on the gastrointestinal mucosa. A study by 
Rausch and co-workers not only found significant differences in the gut microbiome 
of CD patients as compared to controls but also with respect to FUT2 genotype [54]. 
Depending on the FUT2 genotype differences in bacterial composition and, diversity 
were found [54]. 
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Conclusion: 
This review has summarized the most recent findings on the pathogenesis of IBD. 
The more data we obtain the more the puzzle of IBD pathophysiology fits together. 
It becomes very clear that intestinal inflammation arises from a complex interplay 
between genetic factors, environmental factors, dysregulated immune responses and 
alterations in the microbiome. Recent studies reveal that one of these factors alone is 
most likely not sufficient to induce disease. However, the co-incidence of genetic 
variations within susceptibility genes, presence of certain bacteria, viruses or fungi 
affecting intestinal barrier integrity and inflammatory reactions as well as of 
alterations in the intestinal microbiome due to social factors and nutrition results in 
the very end in a modulation of the intestinal immune system finally establishing a 
chronic inflammatory state. Since evidence evolves that each of the genetic factors 
regulates and affects each other the concept of the “limited pathways” gains more 
and more interest. This concept means that the so far discovered genetic risk factors 
explain about 80 % of the currently missing heritability in the pathogenesis of IBD. 
Alltogether, recent findings stronglys demonstrate that IBD is not the result from a 
single event being associated with increased inflammation, but the endpoint of a 
complex network of environmental and invironmental factors being closely related to 
each other. 
Future research will need to further clarify the effects of the microbiome and 
environmental factors on the immune system. It will be essential to gain further 
insights into the mechanisms and pathways how bacteria, viruses and fungi can 
modulate innate and adaptive immune responses and inflammatory events. 
Additionally, it will be of great importance to study how the intestinal flora is affected 
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by the environment and social factors as well as, vice versa, by the flora-induced 
immune responses. According to the limited pathways concept it will be crucial to 
achieve a better understanding of the complex interplay between the different 
susceptibility genes and their relevance for modulating immune responses to 
intestinal antigens. 
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Key points: 
 
• Rising evidence suggests the “limiting-pathway model” for IBD pathogenesis, 
which means that genes and their products may not be independent but 
rather linked in a way that effects of one gene or gene product are modified 
by one or several other genes or their products. 
 
• The observation that IBD risk factors are not independent but functionally 
closely linked to each other is strongly supported by recent findings that 
NOD2, ATG16L1, NLRP3 and ER stress can regulate the expression of each 
other and modify the functional outcome of each other, in example variations 
within the Nod2 gene affect autophagy and inflammasome function. 
 
• Environmental and genetic factors can interact and modify each other, since it 
becomes more and more obvious that one the one hand environmental factors 
cause epigenetic modifications, induce metabolic pathways, interact with 
malfunctioning pathways of the innate immune system or cause responses 
that cannot properly be resolved, while on the other hand genetic variants 
change at least the micro-environment e.g. the composition of our gut flora, 
the microbiome.  
 
• By means of the new sequencing methods environmental factors such as 
geography, economic living conditions, age, diet and lifestyle have been 
shown to influence the composition of the intestinal microbiota what results in 
 21 
specific activation pattern of the immune system as a typical example for an 
environment-gene interaction. 
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Figures: 
 
Figure 1 
Schematic representation of the concept of additive effects (left side) and the limited 
pathway concept representing “epistasis” (right side). Several risk factors contribute 
to the same effector pathways and influence each other’s function. Recent evidence 
suggests direct of functional interactions between Nod2 and Atg16l1 as well as Nlrp3. 
Further evidence (see text) indicates a regulatory function of PTPN2 on autophagy 
function and Nod2 sensing. 
 
Figure 2 
The basic concept of IBD pathophysiology highlighting the “core mechanisms”. 
Environmental factors influence the composition and function of the gut microbiome. 
Whole bacteria, viruses, bacterial wall products or secreted factors such as proteins, 
enzymes or DNA interact with receptors in cells of the mucosal wall. The induce 
reactions such as production of reactive oxygen species (ROS), ER stress, autophagy, 
inflammasome activation and transcription factors activation and translocation. A 
number of signals modulate each other positively or negatively forming a network of 
regulation. Genetic variants in pattern recognition receptors, bacterial processing 
pathways and adaptive immune response molecules such as interleukins and their 
receptor represent branch point in this framework of interactions leading to failures 
of pathways finally resulting in an imbalance of the intended response. 
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